- Mergers & acquisitions
- Equity capital markets
Founded in 2000, ADVANCED BIOLOGICAL LABORATORIES SA (ABL SA) is a fully integrated group specializing in medical diagnostics.
The group develops and markets innovative diagnostic products for infectious diseases such as HIV, tuberculosis and SARS-CoV.
ABL SA’s product offering includes genotyping and molecular detection kits and software for accredited laboratories, CRO services for pharmaceutical laboratories, and clinical software applications and dashboards for research and clinical management. These products developed by the group are aimed at infectious disease clinicians and virology and microbiology laboratories in Europe and around the world.
In 2021, the ABL SA group achieved a turnover of more than €10 million and relies on a team of about sixty people present in Luxembourg, France, Spain, the United States and South Africa.
ATOUT CAPITAL advised the shareholders of ABL SA in the preparation and filing of a Public Tender Offer for ETABLISSEMENTS FAUVET-GIREL (EFG) shares. At the closing of the offer, ABL SA holds 243,481 EFG shares representing 97.08% of the capital and voting rights of this company.
This transaction follows the acquisition by ABL SA in October 2021 of a controlling block shares in EFG from various shareholders. Following this Public Tender Offer, ABL SA intends to transfer its subsidiary ABL France, which specializes in genotyping and molecular detection diagnostics, to EFG and thus to use this listed vehicle to raise funds and accelerate growth.